HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Consumers About Skin-Whitening Injectables

This article was originally published in The Rose Sheet

Executive Summary

A growing number of injectable skin-whitening products are available to consumers through online retailers and other channels, FDA says in an update cautioning the public that such products could pose "significant" safety risks. The agency singles out Flawless Beauty, LLC, which has been subject to recent enforcement activity, including product seizure by U.S. Marshals, but continues to market questionable skin-whitening products with aggressive claims.

You may also be interested in...



Flawless Beauty's Relaunch Pending As Injunction-Mandated Recall Starts

"We didn't want to fight this any further because of the legal fees," said Jack Gindi, owner of the firm. Four months after it agreed to within 20 days recall all lots of 19 products that FDA said were injectable or that contained human placenta, supplement and cosmetic firm Flawless Beauty on Jan. 23 announced the recall.

Federal Court Slaps Injunction On Skin Whitener Seller At FDA's Behest

Ocean Township, N.J.-based Flawless Beauty has been on FDA's radar since 2013, targeted with two facility inspections and a previous complaint that triggered product seizures by US Marshals. Unapproved skin-whitening injectables sold by the company pose potential serious health risks, according to a New Jersey District Court consent decree of permanent injunction against the company and its owners.

FDA Shows Skin Authority Who’s Boss With Warning For Drug Claims

Yet another skin-care marketer, Skin Authority, has been served with an FDA warning letter for excessive product claims that identify its offerings as drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with other warnings issued to cosmetics firms in recent months.

Related Content

UsernamePublicRestriction

Register

RS019635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel